MedTrace Logo

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

NCT05112835 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 302

Last updated 2024-10-29

No results posted yet for this study

Summary

BESRA is a national, multi-center, prospective, observational study to assess the effectiveness of brolucizumab intravitreal injections in patients with nAMD treated in the UK.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

OTHER

brolucizumab

There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2022-09-08
Completion
2022-09-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05112835 on ClinicalTrials.gov